229 related articles for article (PubMed ID: 22532378)
1. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
[TBL] [Abstract][Full Text] [Related]
2. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
[TBL] [Abstract][Full Text] [Related]
3. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
[TBL] [Abstract][Full Text] [Related]
4. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
7. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
[TBL] [Abstract][Full Text] [Related]
9. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Messinger J; Hirvelä L; Husen B; Kangas L; Koskimies P; Pentikäinen O; Saarenketo P; Thole H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):192-8. PubMed ID: 16413669
[TBL] [Abstract][Full Text] [Related]
10. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors with good ADME-related physicochemical parameters.
Perspicace E; Giorgio A; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2013 Nov; 69():201-15. PubMed ID: 24036043
[TBL] [Abstract][Full Text] [Related]
11. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
12. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
15. 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold.
Wetzel M; Marchais-Oberwinkler S; Hartmann RW
Bioorg Med Chem; 2011 Jan; 19(2):807-15. PubMed ID: 21211981
[TBL] [Abstract][Full Text] [Related]
16. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Starcević S; Brozic P; Turk S; Cesar J; Rizner TL; Gobec S
J Med Chem; 2011 Jan; 54(1):248-61. PubMed ID: 21138273
[TBL] [Abstract][Full Text] [Related]
18. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
